Innoviva, Inc. (INVA)
- Simply Wall St.
Innoviva First Quarter 2024 Earnings: EPS: US$0.58 (vs US$0.51 in 1Q 2023)
Innoviva ( NASDAQ:INVA ) First Quarter 2024 Results Key Financial Results Revenue: US$77.5m (up 1.5% from 1Q 2023). Net...
- Business Wire
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
BURLINGAME, Calif., May 08, 2024--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the first quarter ended March 31, 2024, and highlighted select corporate achievements.
- Business Wire
Innoviva to Participate in the BofA Securities Health Care Conference
BURLINGAME, Calif., May 08, 2024--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will present at the BofA Securities Health Care Conference in Las Vegas, NV on Wednesday, May 15, 2024 at 9:20 a
